![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA](https://www.fda.gov/files/Booster%20Infographic_D_Rev_010622_0.png)
Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA
![Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology](https://www.thelancet.com/cms/asset/0feccf25-0e2a-4fb7-b5d2-e6b8d4fdeaf3/gr1.jpg)
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study - The Lancet Oncology
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/figures/mm7011e2-F.gif?_=83873)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule? | British Columbia Medical Journal What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule? | British Columbia Medical Journal](https://bcmj.org/sites/default/files/BCMJ_Vol63_No2-vaccine-dosing_web_Table.jpg)
What is the evidence for extending the SARS-CoV-2 (COVID-19) vaccine dosing schedule? | British Columbia Medical Journal
![Is there a minimum and maximum time interval between COVID-19 vaccine doses? | COVID-19 Info Vaccines Is there a minimum and maximum time interval between COVID-19 vaccine doses? | COVID-19 Info Vaccines](https://assets.website-files.com/619616ca24c2b23d62d214fe/619616ca24c2b26bead21556_60af6e208cd712b108ec605d_60707c493e13d3a28d93e478_602ea8a1ee82987755c657ca_Img_category_coadministration.jpeg)
Is there a minimum and maximum time interval between COVID-19 vaccine doses? | COVID-19 Info Vaccines
![Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ](https://www.bmj.com/content/bmj/373/bmj.n1088/F1.large.jpg)
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study | The BMJ
![Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials - The Lancet](https://www.thelancet.com/cms/asset/643af9b2-1d35-4487-bda0-687f2e80ab01/gr1.jpg)